Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
liujingwen
发表于 2024-10-5 10:59:25
3845
0
0
On October 5th, according to Southern Finance, Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in Brazil that produces a quarter of Novo Nordisk's global insulin production. Novo Nordisk stated in a statement that this funding will be used for a comprehensive overhaul of the Montesquiros factory located in the southeastern state of Minas Gerais, Brazil, and to implement sustainable development projects at the factory. (Interface)
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Novo Nordisk to invest 864 million Brazilian reals to renovate insulin factory in Brazil
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- Novo Nordisk has participated in the CIIE for seven consecutive years, working together with various sectors to promote the concept of "healthy metabolism"
- Novo Nordisk warns of the risk of compound generic semaglutide, which has caused 10 deaths and 100 hospitalizations
- Lai Lai scares, Novo Nordisk saves the scene! The market prospects of weight loss drugs still make many players salivate
- Novo Nordisk: All regulatory delivery conditions for Novo Nordisk's $16.5 billion acquisition of Contante have been met
- Novo Nordisk invests 8.5 billion Danish kroner to build new production facility in Odense, Denmark
- Novo Nordisk's pre-market decline narrows to 20%